This is the department of error for the article Guttman-Yasky E, Kabashima K, Worm M et al. published in the journal Lancet 2026; 407: 53–66. The article reviews the efficacy and safety of rocatinlimab for the treatment of moderate to severe atopic dermatitis in two global, double-blind, placebo-controlled, randomized phase 3 clinical trials: ROCKET-IGNITE and ROCKET-HORIZON. In this department of error, the legend of Table 2 is corrected. The correct wording is: "¶HASS and FASS are instruments that assess the overall severity of AD on the hand and face based on a four-category scale from mild (0) to severe (4)". This change was also made in the appendix on page 29. No other changes or major study findings are reported in this text.